Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature

被引:20
作者
Nakagomi, Yuki [1 ]
Tajiri, Kazuko [1 ,2 ]
Shimada, Saori [3 ]
Li, Siqi [1 ]
Inoue, Keiko [1 ]
Murakata, Yoshiko [1 ]
Murata, Momoko [4 ]
Sakai, Shunsuke [1 ]
Sato, Kimi [1 ]
Ieda, Masaki [1 ]
机构
[1] Univ Tsukuba, Fac Med, Dept Cardiol, Tsukuba, Japan
[2] Natl Canc Ctr Hosp East, Dept Cardiol, Kashiwa, Japan
[3] Univ Tsukuba Hosp, Dept Pharm, Tsukuba, Japan
[4] Univ Tsukuba Hosp, Clin Lab, Tsukuba, Japan
关键词
irAE; immune-related adverse event; cardio-oncology; onco-cardiology; troponin; creatine kinase; PATIENT; MANAGEMENT;
D O I
10.3389/fphar.2022.884776
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Immune checkpoint inhibitor (ICI)-related myositis with myocarditis is a rare but potentially fatal immune-related adverse event. However, its clinical features, response to immunosuppressive treatment, and prognosis remain poorly understood. Here, we describe the clinical course of patients with ICI-related myositis overlapping with myocarditis treated at our institution and a systematic review focusing on the response to immunosuppressive therapy.Methods: We identified patients who developed ICI-induced myositis with myocarditis and were treated at our hospital using a retrospective chart review of electronic medical records. For the systematic review, studies reporting ICI-induced myositis with myocarditis were identified using the Cochrane Library and PubMed databases.Results: Of the 625 patients treated with ICIs, four developed myositis with concurrent myocarditis. All the patients received immunosuppressive therapy. We assessed the activity of myocarditis and myositis based on temporal changes in troponin and creatine kinase (CK) levels. In all patients, peak troponin values appeared later than the peak CK values (median, 17 days). The median time from the start of ICI therapy to the peak of troponin and CK levels was 42.5 and 28 days, respectively. In all patients, CK levels decreased rapidly and steadily after the initiation of immunosuppressants. However, troponin levels were unstable and increased. In all patients, CK levels normalized within one month (range, 12-27 days), but troponin levels took several months to normalize (range, 84-161 days). Fourteen cases of ICI-related myositis with myocarditis were included in the systematic review. Of the 14 cases, 12 (86%) had their CK level decreased after the initial steroid treatment, but the troponin level increased and was higher than that before the start of treatment. In addition, the peak troponin values appeared later than the peak CK values (a median of 6.5 days). Eight (89%) of 9 long-term follow-up patients had troponin levels above the normal range even after CK normalization.Conclusion: In most cases of ICI-related myositis with myocarditis, troponin levels increased after the initial steroid treatment despite decreased CK levels, and exceeded pre-steroid levels. In addition, troponin remained elevated for several months after CK normalized.
引用
收藏
页数:12
相关论文
共 37 条
  • [1] Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors
    Aldrich, Jeffrey
    Pundole, Xerxes
    Tummala, Sudhakar
    Palaskas, Nicolas
    Andersen, Clark R.
    Shoukier, Mahran
    Abdel-Wahab, Noha
    Deswal, Anita
    Suarez-Almazor, Maria E.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 (05) : 885 - 895
  • [2] Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities
    Allenbach, Yves
    Anquetil, Celine
    Manouchehri, Ali
    Benveniste, Olivier
    Lambotte, Olivier
    Lebrun-Vignes, Benedicte
    Spano, Jean-Philippe
    Ederhy, Stephane
    Klatzmann, David
    Rosenzwajg, Michelle
    Fautrel, Bruno
    Cadranel, Jacques
    Johnson, Douglas B.
    Moslehi, Javid J.
    Salem, Joe-Elie
    [J]. AUTOIMMUNITY REVIEWS, 2020, 19 (08)
  • [3] Myocarditis in the Setting of Cancer Therapeutics Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology
    Bonaca, Marc P.
    Olenchock, Benjamin A.
    Salem, Joe-Elie
    Wiviott, Stephen D.
    Ederhy, Stephane
    Cohen, Ariel
    Stewart, Garrick C.
    Choueiri, Toni K.
    Di Carli, Marcelo
    Allenbach, Yves
    Kumbhani, Dharam J.
    Heinzerling, Lucie
    Amiri-Kordestani, Laleh
    Lyon, Alexander R.
    Thavendiranathan, Paaladinesh
    Padera, Robert
    Lichtman, Andrew
    Liu, Peter P.
    Johnson, Douglas B.
    Moslehi, Javid
    [J]. CIRCULATION, 2019, 140 (01) : 80 - 91
  • [4] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
    Brahmer, Julie R.
    Lacchetti, Christina
    Schneider, Bryan J.
    Atkins, Michael B.
    Brassil, Kelly J.
    Caterino, Jeffrey M.
    Chau, Ian
    Ernstoff, Marc S.
    Gardner, Jennifer M.
    Ginex, Pamela
    Hallmeyer, Sigrun
    Chakrabarty, Jennifer Holter
    Leighl, Natasha B.
    Mammen, Jennifer S.
    McDermott, David F.
    Naing, Aung
    Nastoupil, Loretta J.
    Phillips, Tanyanika
    Porter, Laura D.
    Puzanov, Igor
    Reichner, Cristina A.
    Santomasso, Bianca D.
    Seigel, Carole
    Spira, Alexander
    Suarez-Almazor, Maria E.
    Wang, Yinghong
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Thompson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
  • [5] Pembrolizumab-induced autoimmune Stevens-Johnson syndrome/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report
    Cao, Jiashun
    Li, Qiu
    Zhi, Xiuyi
    Yang, Fan
    Zhu, Weipeng
    Zhou, Ting
    Hou, Xianning
    Chen, Donghong
    [J]. TRANSLATIONAL CANCER RESEARCH, 2021, 10 (08) : 3870 - 3876
  • [6] Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
    Curigliano, G.
    Lenihan, D.
    Fradley, M.
    Ganatra, S.
    Barac, A.
    Blaes, A.
    Herrmann, J.
    Porter, C.
    Lyon, A. R.
    Lancellotti, P.
    Patel, A.
    DeCara, J.
    Mitchell, J.
    Harrison, E.
    Moslehi, J.
    Witteles, R.
    Calabro, M. G.
    Orecchia, R.
    de Azambuja, E.
    Zamorano, J. L.
    Krone, R.
    Iakobishvili, Z.
    Carver, J.
    Armenian, S.
    Ky, B.
    Cardinale, D.
    Cipolla, C. M.
    Dent, S.
    Jordan, K.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 (02) : 171 - 190
  • [7] Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report
    Deng, Chao
    Yang, Meng
    Jiang, Hong
    Wang, Renbin
    Yang, Zhaojun
    Sun, Hongliang
    Cui, Huijuan
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
  • [9] Gagnier JJ, 2013, DTSCH ARZTEBL INT, V110, P603, DOI [10.7453/gahmj.2013.008, 10.3238/arztebl.2013.0603, 10.1136/bcr-2013-201554, 10.1186/1752-1947-7-223]
  • [10] Giancaterino Shaun, 2020, HeartRhythm Case Rep, V6, P761, DOI 10.1016/j.hrcr.2020.07.015